Leqembi IQLIK: At-Home Alzheimer's Treatment Brings New Hope

The US approved Leqembi IQLIK, an at-home self-injected Alzheimer's drug by Eisai & Biogen, for patients completing 18 months of IV infusions. Costing $19,500/year, it aims to boost access, convenience, and sales, despite concerns over side effects like brain swelling and bleeding.